QCM
Givinostat
Created: | 2019-10-15 |
Last modified: | 2020-06-05 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 58 |
Chiral Atom Count | 0 |
Bond Count | 60 |
Aromatic Bond Count | 17 |
Chemical Component Summary | |
---|---|
Name | Givinostat |
Synonyms | {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate |
Systematic Name (OpenEye OEToolkits) | [6-(diethylaminomethyl)naphthalen-2-yl]methyl ~{N}-[4-(oxidanylcarbamoyl)phenyl]carbamate |
Formula | C24 H27 N3 O4 |
Molecular Weight | 421.489 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | C(c3ccc(NC(OCc1ccc2c(c1)ccc(c2)CN(CC)CC)=O)cc3)(NO)=O |
SMILES | CACTVS | 3.385 | CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1 |
SMILES | OpenEye OEToolkits | 2.0.7 | CCN(CC)Cc1ccc2cc(ccc2c1)COC(=O)Nc3ccc(cc3)C(=O)NO |
Canonical SMILES | CACTVS | 3.385 | CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1 |
Canonical SMILES | OpenEye OEToolkits | 2.0.7 | CCN(CC)Cc1ccc2cc(ccc2c1)COC(=O)Nc3ccc(cc3)C(=O)NO |
InChI | InChI | 1.03 | InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28) |
InChIKey | InChI | 1.03 | YALNUENQHAQXEA-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB12645 |
---|---|
Name | Givinostat |
Groups |
|
Description | Givinostat is a small molecule histone deacetylase (HDAC) inhibitor. It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies. In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD).[L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316] |
Synonyms |
|
Brand Names | Duvyzat |
Indication | Givinostat is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients ≥6 years of age.[L50311] |
Categories |
|
ATC-Code | M09AX14 |
CAS number | 497833-27-9 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Histone deacetylase | MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRK... | unknown | inhibitor |
Tyrosine-protein kinase JAK2 | MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKS... | unknown | inhibitor |
Histone deacetylase 1 | MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRK... | unknown | inhibitor |
Cytochrome P450 3A4 | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI... | unknown | inhibitor,inducer |
Cytochrome P450 1A2 | MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL... | unknown | inducer |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1213492 |
PubChem | 9804992 |
ChEMBL | CHEMBL1213492 |
ChEBI | CHEBI:94187 |